Decision Resources, Inc., April 2011, Pages: 29
The cancerbiologics pipeline - consisting of antibodies, peptides, and proteins - is robust (vetted to 162 verified agents from an initial list of 639), a notable finding given the high cost
Elsevier Science and Technology, April 2009, Pages: 468
Hyaluronan biology is being recognized as an important regulator of cancer progression. Paradoxically, both hyaluronan (HA) and hyaluronidases, the enzymes that eliminate HA, have also been
Elsevier Science and Technology, Dec 2010, Pages: 400
Advances in molecular biology over the last several decades are being steadily applied to our understanding of the molecular biology of cancer, and these advances in knowledge are being translated
Decision Resources, Inc., Dec 2009, Pages: 26
When cachexia presents, prognosis is poor; that is true in patients with any of several diseases, including cancer. Cachexia affects 80% of patients with advanced cancer and is reported
John Wiley and Sons Ltd, Feb 2009, Pages: 287
The objective of this book is to present to an informed, non-professional audience (i.e., non-cancer researchers and oncologists) our current knowledge about the biology of cancer and its treatment
John Wiley and Sons Ltd, Oct 2007, Pages: 216
. It is essential that staff working with cancer patients understand fully how these new treatments work in order to disseminate timely and appropriate information to patients.
The application of biology
Informa Healthcare, Aug 1998, Pages: 632
research findings in lung cancer research and their applications in patient management.
Biology of Lung Cancer
- discusses available in vivo and in vitro models and their appropriate uses in specific studies
Jain PharmaBiotech, Feb 2012, Pages: 639
concepts of molecular biology of cancer. These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense
Elsevier Science and Technology, Dec 2000, Pages: 372
the past 30 years a big effort has been made to elucidate the molecular mechanisms of cancer metastatis, the leading cause of death for cancer patients. A considerable number of assays have been set up
Select Biosciences Ltd, Jan 2011, Pages: 139
Cancer Vaccine Pipeline
- Personalized Cancer Vaccination Strategies
- Biology and Characteristics of CTCs
- Methodologies/Various Technologies for Enrichment, Detection, and Characterization of CTCs
New MEdicine Inc., Feb 2012
.) mortality and incidence estimates by gender, cancer subtype and stage; estimates of populations carrying certain markers and under treatment by type of therapy.
Mechanism in Malignancy
Etiology
Select Biosciences Ltd, Oct 2011, Pages: 139
including:
- The Various Types of Cancer
- Cardiovascular Disease
- CNS Disorders
- Hepatic Function and Disorders
- Diabetes
- Stem Cell Biology
The emerging field of microRNA biomarkers, micro
Business Insights, Feb 2007, Pages: 105
The cancer market is highly dynamic, creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. These innovations will result in high
John Wiley and Sons Ltd, Jan 2010, Pages: 576
Epidemiology, cure, treatment trials and screening.
3 Biology of cancer.
4 Staging of tumours.
5 Radiotherapy.
6 Systemic treatment for cancer.
7 Supportive care and symptom relief.
8 Medical problems
Jain PharmaBiotech, Feb 2012, Pages: 864
This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well
BioPharm Reports (VennBio Ltd.), Jan 2011, Pages: 195
200 breast cancer markers, reported in studies between 2003 and 2010 inclusive.
Over the last decade, research has generated a wealth of biological data that characterise the changes that occur
BioPharm Reports (VennBio Ltd.), Feb 2011, Pages: 95
significant innovation, as companies establish novel biological strategies to stimulate the immune system to target antigens associated with breast cancer. Of the 22 candidate vaccines in development, 7 (32
